Related Experiment Video
Updated: Aug 12, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Is hypercholesterolemia a risk factor for Alzheimer's disease?
W Gibson Wood1, Urule Igbavboa, Gunter P Eckert
1Department of Pharmacology, University of Minnesota School of Medicine and Geriatric Research, Education and Clinical Center, VA Medical Center, Minneapolis, MN, USA. woodx002@umn.edu
Molecular Neurobiology
|June 15, 2005
Summary
This study reviewed research on cholesterol and Alzheimer's disease (AD). The majority of evidence does not support high cholesterol as a significant risk factor for developing AD.
Area of Science:
- Neuroscience
- Biochemistry
- Gerontology
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder with complex etiology.
- Cholesterol homeostasis is increasingly recognized as a factor in neurological health.
- The potential link between elevated cholesterol and AD risk is a subject of ongoing research.
Purpose of the Study:
- To evaluate the scientific literature regarding the association between cholesterol levels and Alzheimer's disease.
- To determine if elevated serum and brain cholesterol are consistently found in Alzheimer's patients.
Main Methods:
- Systematic review of existing studies examining cholesterol levels in Alzheimer's disease patients and control groups.
- Inclusion of prospective studies and analysis of both serum and brain cholesterol data.
Main Results:
- The majority of reviewed studies do not provide evidence supporting elevated serum or brain cholesterol levels as a risk factor for Alzheimer's disease.
- Inconsistencies were observed in cholesterol level findings across different studies.
Conclusions:
- Current evidence does not strongly link elevated cholesterol to Alzheimer's disease risk.
- Alternative hypotheses, such as the role of cholesterol domains and specific hypercholesterolemic subgroups, warrant further investigation.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...